Home      Tickers | SPY | NQ100 | DOW | Global | ETFs | Sector ETFs | 3x ETFs | ETF Movers | Stock Movers | Trading Alerts
     ^  NVAX:  Intraday  Hourly  Forecast  Similar  Waves  GapOpen  Research  Timing  Gains  Losses  Strategies  Practice
     Fri. Jan. 10, 2020

Trading Signals: NVAX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Fri. Dec. 22, 2023)

(Novavax, Inc.)

Market is closed on Fri. Jan. 10, 2020


Trend Analysis and Forecast
 
Average Daily Percentage Swing  0% (three month average)
RSI   
Latest Price   $(0%)
Stocks Behave Similarly  Similar Stock List
Market Behavior  Broad based sell-off for large cap. Broad based sell-off for small cap.
Correlated ETFs  Broad market will support NVAX advance at 0% a week (0% probability)
  IBUY(7%)    ONLN(7%)    QQQ(7%)    IVW(6%)    IWF(6%)  
Factors Impacting NVAX price  NVAX will advance at least -0% in a week (0% probabilities).
  VCSH(-3%)    VXX(-2%)    UNG(-2%)    TBT(-2%)    GLD(-2%)  
 
 
Relative Volatility  
 
Market Trend Strength  0% (StdDev 0%)
Hourly BBV   0 ()
Intraday Trend   NAN%
  
 

  

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

JUL 7, 2020 Shares of NVAX surged more than 40% on the news ts has received $1.6 to develop and to deliver up to 100 million doses of the company’s late-stage Covid-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed program.
The vaccine, which focuses on boosting the body’s immune system to effectively combat a Covid-19 infection, is currently in phase 1 and phase 2 clinical trials in Australia, with preliminary results expected at the end of this month.

$. NVAX price fluctuates within NAN% (three month std-dev: 0%) daily (68% of days).

getNextHourMoveProbability failed